Physician profile
Morgan Hack
NPI 1194598508
$2,221.53
in general payments reported to CMS, 2019-2025
37 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.53 |
| Education | $276.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $354.42 | 2025 | Tagrisso, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $194.04 | 2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $164.10 | 2025 | Opdivo, Breyanzi |
| Abbvie INC. | $135.64 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.31 | 2025 | Fruzaqla, Vpriv, Iclusig |
| Genentech USA, INC. | $100.52 | 2025 | Itovebi, Venclexta, Polivy |
| Seagen INC. | $99.00 | 2025 | |
| Merck Sharp & Dohme LLC | $94.33 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Jazz Pharmaceuticals INC. | $82.97 | 2025 | |
| Incyte Corporation | $71.70 | 2025 | Zynyz, Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $63.44 | 2025 | |
| Caris Mpi, INC. | $62.82 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $55.65 | 2025 | Reblozyl |
| Genzyme Corporation | $54.22 | 2025 | |
| Genmab U.S., INC. | $45.42 | 2025 | Epkinly, Tivdak |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41.07 | 2025 | Trodelvy |
| Glaxosmithkline, LLC. | $38.65 | 2025 | Ojjaara, Zejula, Jemperli |
| Iovance Biotherapeutics, INC. | $33.67 | 2025 | Amtagvi |
| Array Biopharma INC | $32.71 | 2025 | Mektovi, Lorbrena, Braftovi |
| Sumitomo Pharma America, INC. | $27.90 | 2025 | Orgovyx |
| Kyowa Kirin, INC. | $27.12 | 2025 | |
| Karyopharm Therapeutics INC. | $26.98 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.89 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.51 | 2025 | |
| Lilly USA, LLC | $22.46 | 2025 | Verzenio, Jaypirca |
| Tersera Therapeutics LLC | $22.06 | 2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $21.62 | 2025 | Romvimza, Qinlock |
| Astellas Pharma US INC | $21.58 | 2025 | Xtandi |
| Accord Healthcare, INC. | $21.30 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.09 | 2025 | Ultomiris |
| Pharmaessentia USA Corporation | $20.91 | 2025 | Besremi |
| Coherus Oncology, INC. | $17.11 | 2025 | Loqtorzi |
| Alnylam Pharmaceuticals INC. | $15.52 | 2025 | Givlaari |
| Novocure INC. | $15.52 | 2025 | Optune Lua (Novottf-200t) |
| Stemline Therapeutics INC. | $15.20 | 2025 | Orserdu |
| Pfizer INC. | $15.10 | 2025 | |
| Eisai INC. | $13.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.